| Patent Number |
Title Of Patent |
Date Issued |
| 8278435 |
N-pyrazole A2A receptor agonists |
October 2, 2012 |
| The present disclosure provides a process for the preparation of 2-adenosine N-pyrazole compounds exemplified by the structure shown below that are potent and selective agonists for A.sub.2A adenosine receptor, compositions comprising these compounds, and methods for using these comp |
| 8188099 |
Method of decreasing hepatotoxic side effects using A.sub.2B adenosine receptor antagonists |
May 29, 2012 |
| The invention is related to a method of decreasing hepatotoxic side effects using an A2B adenosine receptor antagonist and utility in the treatment of liver damage caused by undergoing hepatotoxic treatment, such as chemotherapy or radiation. The invention also relates to pharmaceuti |
| 8133879 |
Myocardial perfusion imaging methods and compositions |
March 13, 2012 |
| The present disclosure provides 2-adenosine N-pyrazole compounds of structural formula shown below that are potent and selective agonists for A.sub.2A adenosine receptor, compositions comprising these compounds, and methods for using these compounds in a variety of applications including |
| 8106029 |
Use of A.sub.2A adenosine receptor agonists |
January 31, 2012 |
| Myocardial imaging methods are provided that are accomplished by administering doses of a pharmaceutical composition comprising one or more adenosine A.sub.2A receptor agonists, in particular regadenoson, useful for, among other indications, myocardial imaging and coronary vasodilati |
| 8071566 |
Methods of coronary imaging |
December 6, 2011 |
| The present invention provides methods of myocardial perfusion imaging and increasing coronary blood flow of a mammal that are accomplished by administering doses of a compound that is a selective partial A.sub.2A receptor agonist with a short duration of action, in particular regade |
| 7795268 |
Method of treating hepatic disease using A.sub.2B adenosine receptor antagonists |
September 14, 2010 |
| The invention is related to methods of treating hepatic fibrosis using A.sub.2B adenosine receptor antagonists and utility in the treatment of liver damage caused by alcohol abuse, surgical intervention, viral hepatitis, the ingestion of hepatotoxic drugs, or other hepatic diseases. |
| 7655637 |
N-pyrazole A.sub.2A receptor agonists |
February 2, 2010 |
| 2-adenosine N-pyrazole compounds having the following formula: ##STR00001## wherein R.sup.1.dbd.CH.sub.2OH; R.sup.2 is hydrogen; R.sup.3 is selected from the group consisting of CO.sub.2R.sup.20; --CONR.sup.7R.sup.8 ,and aryl wherein the aryl substituent is optionally substituted wi |
| 7655636 |
Use of A2A adenosine receptor agonists |
February 2, 2010 |
| The present invention relates to methods for producing coronary vasodilation with little peripheral vasodilation by administering doses of a pharmaceutical composition including regadenoson, named (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminop- urin-2-yl}pyr |
| 7479485 |
Method of treating arrhythmias |
January 20, 2009 |
| Methods are provided for treating arrhythmia in a manner that minimizes undesirable side effects, comprising administration of a therapeutically effective minimal dose of an A.sub.1 adenosine receptor agonist with a therapeutically effective minimal dose of a beta blocker, calcium channe |
| 7183264 |
N-pyrazole A2A receptor agonists |
February 27, 2007 |
| 2-adenosine N-pyrazole compounds having the following formula: ##STR00001## and methods for using the compounds as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart are disclosed. |
| 7144872 |
N-pyrazole A.sub.2A receptor agonists |
December 5, 2006 |
| This specification discloses 2-adenosine N-pyrazole compounds having the following formula: ##STR00001## and methods for using the compounds as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart. |
